- Home
- GSL vs KPTI Comparison
GSL vs KPTI Comparison
Compare GSL & KPTI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GSL
- KPTI
- Stock Information
- Founded
- GSL 2007
- KPTI 2008
- Country
- GSL Greece
- KPTI United States
- Employees
- GSL N/A
- KPTI 279
- Industry
- GSL Marine Transportation
- KPTI Biotechnology: Pharmaceutical Preparations
- Sector
- GSL Consumer Discretionary
- KPTI Health Care
- Exchange
- GSL Nasdaq
- KPTI Nasdaq
- Market Cap
- GSL N/A
- KPTI 29.8M
- IPO Year
- GSL 2006
- KPTI 2013
- Fundamental
- Price
- GSL $23.11
- KPTI $3.54
- Analyst Decision
- GSL Strong Buy
- KPTI Strong Buy
- Analyst Count
- GSL 1
- KPTI 5
- Target Price
- GSL $29.00
- KPTI $61.00
- AVG Volume (30 Days)
- GSL 415.0K
- KPTI 148.6K
- Earning Date
- GSL 03-05-2025
- KPTI 05-07-2025
- Dividend Yield
- GSL 7.79%
- KPTI N/A
- EPS Growth
- GSL 17.78
- KPTI N/A
- EPS
- GSL 9.67
- KPTI N/A
- Revenue
- GSL $705,529,000.00
- KPTI $145,237,000.00
- Revenue This Year
- GSL N/A
- KPTI $4.87
- Revenue Next Year
- GSL N/A
- KPTI $16.29
- P/E Ratio
- GSL $2.36
- KPTI N/A
- Revenue Growth
- GSL 5.82
- KPTI N/A
- 52 Week Low
- GSL $20.11
- KPTI $3.51
- 52 Week High
- GSL $30.32
- KPTI $23.40
- Technical
- Relative Strength Index (RSI)
- GSL 52.01
- KPTI 24.18
- Support Level
- GSL $22.42
- KPTI $5.90
- Resistance Level
- GSL $23.90
- KPTI $6.69
- Average True Range (ATR)
- GSL 0.51
- KPTI 0.61
- MACD
- GSL -0.08
- KPTI -0.20
- Stochastic Oscillator
- GSL 44.23
- KPTI 0.26
About KPTI Karyopharm Therapeutics Inc.
Karyopharm Therapeutics Inc is a commercial-stage pharmaceutical company pioneering novel cancer therapies and dedicated to the discovery, development, and commercialization of drugs directed against nuclear export for the treatment of cancer and other diseases. XPOVIO (selinexor), is approved in the U.S. in multiple hematologic malignancy indications, including in combination with Velcade (bortezomib) and dexamethasone for the treatment of adult patients with multiple myeloma after at least one prior therapy, in combination with dexamethasone for the treatment of adult patients with heavily pretreated multiple myeloma and as a monotherapy for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma. The company derives its revenue from United States.